One hundred fifty-two bacterial strains that possess resistance to kanamycin A, gentamicin, or tobramycin, or to more than one of these antibiotics, were collected from various sources in Canada, Europe, Japan, and the United States. This collection was composed of Staphylococcus aureus and Pseudomonas aeruginosa and members of the Enterobacteriaceae family. Their susceptibility to BB-K8 (amikacin), a new broad-spectrum semisynthetic derivative of kanamycin A, and to the other agents, was determined on Mueller-Hinton Medium by the twofold agar dilution method. Test results revealed that 60.5% of the isolates were resistant to 8 gg of tobramycin per ml, 67.1% to 8 ,g of gentamicin per ml, 86.2% to 20 ,g of kanamycin A per ml, and only 8.6% to 20 ig of amikacin per ml. Of interest is the fact that the amikacin-resistant strains were generally resistant to all of the other aminoglycosides. The broad spectrum of amikacin was not totally unexpected, because the compound has been shown to be a poor substrate for most enzymes that inactivate other aminoglycosides through O-phosphorylation, O-adenylylation, or N-acetylation. A number of susceptibility profiles were obtained when the organisms were tested against a series of nine aminoglycosides. The majority of these profiles resembled those found for organisms that possess known mechanisms of enzymatic inactivation.
Gentamicin has proven to be active against most kanamycin-resistant strains of Staphylococcus and Enterobacteriaceae and, in addition, has been found markedly inhibitory for most strains of Pseudomonas aeruginosa, a species totally refractory to kanamycin (M. J. Weinstein, First Int. Symp., Paris, p. 9-18, 1967) . Although reports of gentamicin resistance among clinical isolates were rare during the first several years of its use, such resistance is now being encountered frequently, particularly among strains of Providencia, Proteus, and Pseudomonas sp. (1, 8, 14, 20, 21, 31, 36) .
The discovery of tobramycin in the fermentation broths of Streptomyces tenebrarius provided an antibiotic that is as active as gentamicin against most strains of Enterobacteriaceae and has activity at least twofold greater against P. aeruginosa. Interestingly, there have already been reports describing clinical isolates that are resistant to tobramycin (6, 8) . However, not all of these strains have been found to be resistant to gentamicin (13, 15, 27) . This is not too surprising since it is now known that some gram-negative bacilli produce an R-factormediated enzyme (10) that inactivates gentamicin but not tobramycin, although at least three other enzymes (2, 3, 38) readily inactivate both antibiotics.
A recently synthesized kanamycin derivative, BB-K8 (19) , is active against a high percentage of gentaffiicin-resistant strains of P. aeruginosa and Enterobacteriaceae (30) . This antibiotic, which now has the generic name "amikacin," either does not serve as a substrate or is only a poor one for three of the four enzymes that inactivate gentamicin and for two of the three that affect tobramycin. Furthermore, growth of some species of organisms producing the one enzyme that does affect amikacin may still be inhibited by relatively low concentrations of the antibiotic. Thus, on the basis of its unique ability to resist enzymatic attack, one would expect amikacin to have significant activity against many gentamicin-and tobramycinresistant microbial strains.
The present study was undertaken to explore this suggestion and to attempt to gain insight into the relative incidence of O-phosphorylating, O-adenylylating, and N-acetylating enzymes produced by a collection of clinical strains of Staphylococcus aureus, P. aeruginosa, In vitro antibacterial activity. Minimal inhibitory concentrations (MIC) of the nine antibiotics studied were determined by means of an agar dilution procedure in which standardized bacterial inocula were deposited on the surface of agar plates with the multiple inoculator device described by Steers, Foltz, and Graves (32 (2) . The labeled substrates were obtained from Amersham-Searle. Radioactivity was determined with a Tri-Carb liquid scintillation spectrometer (Packard Instrument Co.).
Therapeutic effectiveness of aminoglycoside antibiotics. Selected strains resistant to aminoglycosides by virtue of known or suspected enzymatic inactivation mechanisms were used to produce experimental infections in mice. Organisms making up the challenge dose were suspended in 4% mucin and administered in 0.5-ml volume by the intraperitoneal route to male Swiss-Webster mice having individual weights of 20 ± 2 g. The number of cells administered was sufficient to kill all untreated mice within 48 h. Antibiotic treatment was administered by the intramuscular (i.m.) route at 1 and 4 h postchallenge or, in the case of several therapeutically refractive P. aeruginosa infections, at 0, 2, 4, and 6 h postchallenge. In all cases, dose responses were determined with five to six drug dosages that varied by fourfold increments and with five animals per dosage level. At the SUSCEPTIBILIrY OF 152 ISOLATES TO BB-K8 145 conclusion of the experiment (usually day 5), the total number of surviving mice was recorded and the PD,0 (the dose in milligram per kilogram per treatment which protected 50% of the animals) was estimated by means of a log-probit plot.
RESULTS
Susceptibility to aminoglycoside antibiotics. Initially, 152 aminoglycoside-resistant bacterial strains were tested by the agar dilution susceptibility test method against the following antibiotics: kanamycin, gentamicin, tobramycin, and amikacin. The criteria of susceptibility chosen for this study were based on the mean peak serum concentrations achievable in humans after i.m. administration of doses recommended for routine therapeutic use. This procedure has been used previously by others to assign clinical strains to susceptible or resistant categories (20, 41) .
Kanamycin, when given in a standard dose of 7.5 mg/kg, produces an average peak serum level of about 20 ,g/ml (20, 24) , whereas gentamicin, at the commonly used dose of 1.6 mg/kg, gives a peak of approximately 8 gg/ml (5 Table 1 is the number of sources from which members of each species were acquired. It seems likely that, the greater the number of sources, the greater the probability that the organisms utilized are truly different strains rather than different isolates of the same strain.
All but one of 36 E. coli and Enterobacter strains studied were resistant to kanamycin; 18 were resistant to gentamicin and 19 were resistant to tobramycin. Only 7 of the 36 strains were resistant to amikacin. The pattem found for K. pneumoniae strains was similar, although the number of strains resistant to gentamicin and tobramycin was slightly higher. All were susceptible to amikacin and all resistant to kanamycin.
Gentamicin and tobramycin failed to inhibit the growth of the majority of Proteus and Providencia strains. Kanamycin, however, in contrast to what had been found for the previously discussed species, inhibited many of these isolates, and all but one of the 41 strains in these two groups were susceptible to amikacin.
An interesting variation in the pattern of resistance to aminoglycoside antibiotics was observed in strains of S. marcescens. With this species, the percentage of strains resistant to both kanamycin and tobramycin was quite high, whereas gentamicin, in sharp contrast, inhibited 12 of the 18 strains tested. None of the 18 Serratia strains was resistant to amikacin.
Single strains of Salmonella derby, S. panama, and S. orienburg were each found resistant to kanamycin but not to the other antibiotics. An interesting resistant profile was also noted for the 34 strains of P. aeruginosa. The finding that all isolates were resistant to kanamycin was not surprising since it is an antibiotic that appears to be devoid of activity against this species. However, the fact that only 16 Profiles of strains resistant to three antibiotics varied widely in their incidence. For example, 49 strains showed resistance to KGT. This was, therefore, the most common profile identi- 5Pseudomonas aeruginosa strains were selected so that representative isolates possessing resistance to kanamycin only were excluded from the study. c Includes seven strains of Staphylococcus aureus and three strains of Salmonella species which were also resistant to kanamycin. fied in the entire study. In contrast, only one strain showed resistance to KGA. No KTA or GTA patterns were found among any of the isolates. Resistance to all four antibiotics (pattem KGTA) was detected in 12 instances and occurred primarily in E. coli, Enterobacter, and P. aeruginosa strains.
Some of the patterns (K and KGT) were widely distributed among members of almost all species examined, whereas other patterns were more restricted in their distribution. For example, T was encountered only in strains of P. stuartii, and KG almost exclusively (17 of 19 times) in strains of P. aeruginosa. Similarly, the distribution of GT was also restricted and was observed only in Proteus and Providencia sp.
Resistance profiles obtained with nine aminoglycoside antibiotics. Since amikacin acts as a poor substrate for most aminoglycoside-inactivating enzymes (30) , it seems probable that the low incidence of resistance to the compound noted in the preceding experiments may be attributed to this property. However, because of the obvious difficulties presented by an effort to examine the specific enzyme-producing capability of each member of this large group of 152 bacterial strains, an alternate approach was employed in an effort to gain some information in this regard. Previous studies at Bristol Laboratories have shown that organisms possessing a known inactivating enzyme(s) give a characteristic "resistance profile" when tested against nine selected aminoglycoside antibiotics. It seemed of interest. therefore, to test the present group of clinical isolates against this same series of nine aminoglycosides to determine whether the resistance profiles found were all similar to those previously observed or whether new profiles could be detected. Table 3 shows 10 resistance profiles that would be expected for organisms which produce the enzymes listed in the last column. For each of 10 enzymes or combinations of enzymes listed, a characteristic profile was obtained. These profiles were deduced from our present knowledge of enzymatic inactivation in resistant strains; it is possible, of course, that an as yet undescribed inactivating mechanism could give rise to similar profiles. Also included in Table 3 is an additional group of six profiles whose characteristics differ from those attributable to organisms with a known enzyme complement. It has not yet been determined whether all organisms displaying such profiles actually produce aminoglycoside-inactivating enzymes.
Patterns 1, 2, and 3 occurred as a result of the action of the plasmid-mediated enzymes, neomycin-kanamycin phosphotransferases I and II (NPT, and NPT1l), which phosphorylate the 3'-OH of antibiotics having this function present in the 4-substituent of 2-deoxystreptamine (2-DOS), or the 5"-OH of the ribose moiety of lividomycins (9, 16, 17, 22, 23, 27, 34, 39) .
The next profile (no. 4) is attributable to the transferable R-factor-mediated enzyme, gentamicin adenylylate synthetase (GAS), that expresses itself through the mechanism of 0-adenylylation at the 2"-OH group of aminohexoses glycosidically linked at the 6-position of 2-DOS (2, 3, 30, 37). Profiles 5 and 6 were obtained with combinations of GAS with NPT1 and with NPTI,, respectively, and gave the indicated patterns of resistance.
Pattern 7 occurred with strains that produce gentamicin acetyltransferase (GAT,), a highly specific enzyme that acetylates the C-3 amino group of the 2-DOS moiety of gentamicins (10) . The enzyme appears to be plasmid-mediated in some strains of Enterobacteriaceae (35) . Pattern 8 was observed with strains that produce GAT, and a low level of phosphorylating enzymes. Studies measuring uptake of 32P from 32P-ATP indicated that both NPT, and NPTI1 may be present in cell-free preparations of these strains. The next pattern (no. 9) occurred as a result of inactivation produced by gentamicin acetyltransferase II (Gat,,) which acetylates the 2'-amino group of the aminoglucose moiety of neamine and neamine-like components of this group of antibiotics (3). Thus far, no information is available as to whether this type of resistance is associated with the bacterial chromosome or with a transferable plasmid.
Pattern 10 occurred with isolates that produce kanamycin acetyltransferase (KAT). This plasmid-mediated enzyme is transferable and has as its site of action the 6'-amino group that is present in the aminoglucose portion of the antibiotics' neamine or neamine-related moieties (28, 33, 40) .
The enzyme complement of strains producing the remaining patterns is unknown. Pattem 11 is characteristic of strains that are resistant to kanamycin and tobramycin, but susceptible to gentamicin and amikacin. Pattem 12 is similar except that the test strains are also susceptible to all pentose-containing antibiotics other than butirosin. Of interest is the fact that all six strains which displayed this pattern were S. marcescens strains that possess acetylating activity (K. Price, unpublished data).
Patterns 13 and 14 were obtained with isolates that were resistant to kanamycin and VOL. 5, 1974 on October 14, 2017 by guest http://aac.asm.org/ Overall, in the case of the 95 strains with known resistance patterns (1 to 10), and therefore thought to be enzyme producers, kanamycin was the antibiotic most susceptible to inactivation, for it could be phosphorylated, adenylylated, or acetylated. The pentose-containing aminoglycosides, on the other hand, could also be phosphorylated and acetylated but were not subject to adenylylation. Tobramycin, gentamicin, and DKB can be inactivated either through adenylylation or acetylation, while amikacin activity is affected by only one type of acetyltransferase (KAT).
Categorization of strains according to species and type of resistance profile. Table 4 shows the number of strains, among the 152 investigated in this study, which could appropriately be assigned on the basis of their resistance pattern to one of the 16 profiles shown in Table  3 . Eighteen of the test organisms had a resistance profile identical to that observed in bacterial strains which produce NPTI. This profile is widely distributed and was found among representatives of five different genera of Enterobacteriaceae. The distribution of profile 2, which is typical of that obtained with NPT,,-producing strains, was more restricted and occurred in only two species (E. coli and E. cloacae). The incidence of these strains was lower than that of strains producing NPTI.
Interestingly, the pattern produced by the combination of NPT, and NPT1, did not occur in any of the same species in which a pattern produced by a single phosphorylating enzyme was found. The combination pattern (no. 3) was equally distributed among strains of Providencia and Staphylococcus sp. It is likely, that, if wild-type P. aeruginosa strains, i.e., those that are resistant to kanamycin but susceptible to gentamicin, tobramycin, and amikacin, had been included in the study, a high percentage would have been found to have this same resistance profile.
The profile (no. 4) of strains that produce GAS alone was observed in only 3 of 152 species. However, patterns like those produced when GAS is present in combination with a phosphorylating enzyme (no. 5 and 6) were observed more often. Overall, 17 strains had resistance profiles which suggested that a combination of 148 PRICE ET AL. GAT, alone produces a characteristic pattern (no. 7) which was only rarely encountered in the present series of 152 isolates. However, the profile observed with the combination of GAT, and phosphorylating enzymes (no. 8) occurred relatively frequently, but exclusively, in strains of P. aeruginosa. The presence of GAT, in this species could thus account for the rather high incidence of gentamicin-resistant, tobramycinsensitive P. aeruginosa strains observed in this study and probably for those found in the series of P. aeruginosa strains studied by Burger, Sanford, and Zweighaft (11).
Pattern 9, which is characteristic of that obtained with organisms which produce GAT1,, was found exclusively in members of the Proteeae tribe, specifically Proteus sp. and P. stuartii. Because kanamycin does not serve as a substrate for GAT,, and is therefore inhibitory for the producing organisms in in vitro susceptibility tests, this pattern is readily identifiable. Pattern 10 is that observed for organisms producing KAT only. The presence of this pattern was observed in only 1 have caused an increase in the number of gentamicin-resistant, tobramycin-sensitive strains, whereas additional S. marcescens strains would have produced the opposite result. Similarly, inclusion of a greater number of Proteus and Providencia isolates probably would have increased significantly the number of strains susceptible to kanamycin, but resistant to gentamicin and tobramycin. These predictions are based on the observation that certain species are more likely than others to possess genes that mediate specific inactivating enzymes.
Although it is recognized that the nature of the strains examined could have a marked influence on the type of results obtained, it is likely that the distribution of resistance profiles observed in this study has some significance. The mere fact that there was a relatively wide variation in the number of strains of each species available for incorporation into the study may be meaningful in itself, since it gives some indication as to the relative frequency of aminoglycoside resistance among strains which, at least with respect to their species classification, were collected on a random basis. Those species with the greatest representation in this collection probably are the ones with the highest overall incidence of resistance to aminoglycosides in the clinical environment. The data obtained in this study were not merely the result of conditions that exist within a localized setting, since the isolates examined were obtained from many and diverse sources. In fact, on average, only about two resistant strains were obtained from each source.
Amikacin, as predicted, displayed remarkable effectiveness against strains resistant to other aminoglycosides. Only 13 of the 102 gentamicin-resistant strains and 12 of the 92 tobramycin-resistant strains were refractory to this antibiotic. Particularly noteworthy is the fact that all but one of the amikacin-resistant strains were commonly resistant to gentamicin, tobramycin, and kanamycin.
Thus, among aminoglycoside-resistant organisms, the spectrum of amikacin appears to be broader than that of the other three aminoglycoside antibiotics. When resistance to amikacin occurs, the probability is high that resistance to other aminoglycosides will also be present.
